Abstract -Studies of the biosynthesis of aminocyclitol antibiotics, especially neomYcin, have led to development of the mutasynthetic technique for the preparation of related antibiotics. A specific type of mutant strain of the microorganism which normally produces the aminocyclitol antibiotic is first prepared. The mutant sought is one unable to produce the aminocyclitol subunit and thus it can produce the normal antibiotic only in the presence of added native aminocyclitol. Alternatively, it can produce related (mutasynthetic) antibiotics in the presence of other aminocyclitols (mutasynthons). Mutasynthesis is not limited to aminocyclitol antibiotics but it has now been used to produce compounds related to essentially all of the clinically useful aminocyclitol antibiotics. Not all potential mutasynthons are accepted by the mutants and some accepted lead to antibiotics more widely altered than by the simple substitution of a natural by an unnatural aminocyclitol. Thus, mutasynthesis has considerable potential in the study of the structural requirements for bioactivity as well as in the design of new antibiotics.
The search for new antibiotics follows many trails {1,2). The classical biological approach is that of screening, in which a soil sample is examined for the microorganisms which produce antibiotics. Although somewhat random, this method has led historically to some of the greatest successes in chemotherapy through the discovery of tetracycline, cephalosporin, chloramphenicol and erythromYcin, to name but a few. As Screening has become more expensive and the probability of finding a new antibiotic statistically less attractive, newer approaches to the development of antibiotics have been investigated. A number of these newer procedures are at least partially chemical in nature. Total synthesis has only rarely provided useful new antibiotics due to the complexity of the .structures involved, with their many asymmetric centers. However, partial synthesis has provided us with the semisynthetic penicillins and other useful chemotherapeutic agents (3), while chemical modification of older antibiotics, such as the conversion of rifamYcin B to rifampicin (4) and that of lincomycin to clindamycin (5) , has also proved successful. What I shall discuss here is a different approach to the preparation of new antibiotics, a procedure for which we have coined the term mutasynthesis.
The mutasynthetic technique is an outgrowth of our studies on the biosynthesis of aminocyclitol antibiotics (6) and I should like to turn first to that subject. Representatives of this class of antibiotics are characterized by the presence of an aminocyclohexanol or related subunit and include StreptomYcin and neomYcin, which were among the first antibiotics discovered. The class has maintained a place of importance in chemotherapy through the more recent additions of kanamycin, gentamicin, spectinomYCin, and ribostamycin to the list of clinically useful compounds. Clinically useful antibiotics of this class are shown in Figs. 1-3. As is evident from the figures the class can be further divided into subclasses consisting of those which contain deoxystreptamine (neomYcins, ribostamYcin, kanamycins, gentamicins) and those which do not. Among the latter, StreptomYcin (which contains streptidine, a substituted streptamine) and spectinomYcin (which contains actinamine, a substituted 2-epistreptamine) are the most important.
The particular aminocyclitol antibiotic we chose to study firstwas neomYcin, whose structure, shown in Fig. 1 , we had assigned over a period of several years (7) . NeomYcin is produced by Streptomyces fradiae and is a potent inhibitor of gram-positive organisms, including MYcobacteria. Used initially in the treatment of tuberculosis, its nephrotoxicity and ototoxicity have more recently restricted its use to topical applications and oral administration prior to intestinal surgery. Biosynthesis of neomycin has been mainly studied by adding labeled precursors to cultures of Streptomyces fradiae growing in shake flasks, isolating the antibiotic, and locating label. Radioactive precursors were originally employed (8) , but a more convincing demonstration of the nature of the precursors has been obtained using 13c labeling and 13c NMR to locate label (9) . •. Before the 13c incorporation results could be interpreted~ of course, all the signals in the 1 C NMR spectrum of neomYcfn B had to be assigned and 13c-labeled precursors had tobe prepared. For the study of its 13c NMR spectrum, the antibiotic was first converted to its hexa-N-acetyl derivative, whose spectrum is shown in Fig. 4 . This spectrum was then reconstructed from those of its subunits shown in Fig. 5 , starting with that of the simplest, di-N-acetyldeoxystreptamine, .and proceeding through tetra-N-acetylneamine to tetra-N-acetylribostamycin which, with methyl di-N-acetylneosaminide B, provided a composite model for hexa-N-acetylneomYcin B (10) . Once the 13c NMR spectrum of unlabeled hexa-N-acetylneomYcin B was established it was simple to interpret the spectrum of the same compound, also shown in Fig. 4 , isolated from biosynthetic experiments employing [6-13c] 
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These spectra demonstrated that C-6 of glucose labels C-6 of neosamines B and C (units B and C, respectively, in Fig. 5 ) and C-5 of ribose (unit R in Fig. 5 ) as well as C-2 of deoxystreptamine (unit D in Fig. 5 ), that C-l of glucosamine labels C-1 of neosamines Band C, C-1 of ribose and C-1 of deoxystreptamine (Fig. 7) . Theseexperiments also demonstrated that glucosamine is the more direct precursor of the neosamines, but glucose is the more direct precursor of deoXlstreptamine and ribose. The latter result was confirmed by an experiment employing ~5N]glucosamine, which demonstrated that isotope was incorporated into the neosamines but not into deoxystreptamine. Thus, the biosynthetic labeling pathway shown in Fig. 8 was established for the neomycin subunits.
More important from the Standpoint of the development of the mutasynthetic technique was the demonstration of steps beyend the subunits. Of the four C5 and C5 units only Q-ribose and deoxystreptamine could be demonstrated to be incorporated directly into neomYcin; neosamine C (and presumably neosamine B) was not. These incorporation sturlies were carried out ( The demonstration that deoxystreptamine was incorporated as a unit led us to adopt a different approach, the mutant approach, in our biosynthetic studies. Specifically, a mutant of Streptomyces fradiae was sought which could not biosynthesize deoxystreptamine, hence could not biosynthesize neomycin. The experiments were carried out by treating a growing culture of S. fradiae with a mutagen (normally nitrosoguanidine) to kill nearly all of the cells, in the hopes that the few survivors had mutated. This was easily tested by replicate plating--growing the survivors in media both with and without added deoxystreptamine. Such a mutant (a o-mutant) of S. fradiae was found after many attempts (13) . In addition to confirming the direct place of deoxystreptamine on the biosynthetic pathway the mutant allowed the testing of other potential neomYcin precursors containing deoxystreptamine--neamine and ribostamYcin (14) , ribosyl-deoxystreptamine and neobiosaminyl(B Most important1y, the existence of this o-mutant a11owed us to test the concept of mutasynthesis. The mutant of S. fradiae which cou1d produce neomYcin on1y in the presence of added deoxystreptamine was next tested for whether aminocyc1i-to1s c1ose1y re1ated to deoxystreptamine wou1d be accepted by the mutant as rep1acements for deoxystreptamine and used to produce new antibiotics re1ated to neomYcin. This is the technique for producing new antibiotics which we now ca11 mutasynthesis. Corresponding1y, any antibiotics produced by the procedure are referred to as mutasynthetic Note a: The 1atter two compounds were provided by Professor S. Hanessian, University of Montrea1. antibiotics, while the surrogate aminocyclitols added to the fermentation broth are referred to as mutasynthons.
In a successful mutasynthesis experiment at least four distinct steps are required: preparation of the mutasynthon, incorporation of the mutasynthon, isolation and characterization of the mutasynthetic antibiotic, and biological evaluation of the mutasynthetic antibiotic. We shall turn first to the preparation of the mutasynthons.
In initial studies with the StreptomYces fradiae mutant (17), a total of 30 aminocyclitols and substituted aminocyclitols were tested as mutasynthons and others have been tested in later studies (18). These compounds are shown in Figs. 11-13. Several were readily prepared by hydrolysis of other antibiotics, such as streptidine and streptamine (from Other aminocyclitols, such as 2,5-and 2,6-dideoxystreptamine (or their polyacetyl derivatives) were obtained from other laboratories (Note b), while still others, e.g., 2-epi-, 6-epi, and 2,6-diepistreptamine, were synthesized in our laboratory by routes involving cyclization of nitrohexosamines (20).
The second step involved in mutasynthesis of a new antibiotic is the one least under the control of the chemist, since the organism either accepts the mutasynthon or it does not. A standard fermentation of the mutant strain is carried out except that the mutasynthon, the aminocyclitol, is added to the fermentation medium. lf, after completion of the fermentation, the broth inhibits growth of an appropriate test organism, a new antibiotic may be Note b: Especially that of Professor T. Suami at Keio University.
presumed to have been formed, although it must first be isolated and characterized. With the original mutant strain of Streptomyces fradiae, only two aminocyclitols served as successful 'mutasynthons--streptamine and 2-epistreptamine (Fig. 12) . However, additional mutants of ~· fradiae (Note c) have been testedas well, and some of these mutants gave new antibiotics with mono-N-methyldeoxystreptamine, streptidine, 2,5-and 2,6-dideoxystreptamines, and 2-bromo-and 6-bromostreptamines in addition to streptamine and 2-epistreptamine (Figs. 12, 13). 2,6-Dideoxystreptamine has also recently been employed by Gero, Akhtar, et al., to give 6-deoxyneomycin from a mutant of ~· fradiae (19).
--Isolation and purification of the mutasynthetic antibiotics follow standard procedures for neomycin, mainly ion exchange and ion exclusion chromatography. The mutasynthetic antibiotic produced by addition of streptamine was termed hybrimycin A and that from 2-epistreptamine hybrimycin B, the name hybrimycin being applied since their structures (Fig. 12) were in a sense "hybrids" of neomycin and streptomycin or neomycin and spectinomycin. Paper chromatography demonstrated that hybrimycinsA and B consisted of two components each (hybrimycins Al and A2, Bl and B2) which appeared from Rf values and rotational differences to be related to one another as neomycin B is related to neomycin C (13).
More conclusive evidence has been provided by mass spectrometry. In earlier characterization it was necessary to derivatize the highly polar antibiotics to obtain their mass spectra. Those chosen, the N-acetyl-0-trimsyl and the N,O-trimsyl derivatives, have quite high molecular weights (Fig. 14) , but they are sufficiently volatile for direct probe electron Note c: Obtained from Dr. G. Kimura, Tokyo Tanabe Co.
impact mass spectrometry and the pertrimsyl derivatives will even pass through a gas chromatograph for combination with mass spectrometry (21) . Characteristic fragment ions are also observed in their mass spectra (Fig. 14) . More recently we have characterized mutasynthetic antibiotics by field desorption mass spectrometry (22 Fig. 15 . Field desorption mass spectra of neomYcin B, of subunits of neomYein B, and of hybrimYcin B2, whose·structure is shown in Fig. 12 . Note the shift of all peaks of neomYcin B by 16 amu in the spectrum of hybrimYcin B2, due to its extra oxygen atom.
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identifiable resonances for all 23 carbon atoms, as we saw in Fig. 4 . By comparing the 13c NMR spectrum of hybrimYcin Bl with that of neomycin C (Fig. 16 ) one can see immediately that the methylene carbon (C-2, at 29.6 ppm) of deoxystreptamine has been lost; it is replaced by a new carbinol absorption, located at 70.0 ppm, while the only other carbons at slightly different chemical shifts in the two antibiotics are those near C-2 of deoxystreptamine, 1·~·· C-1, C-3, C-4, and C-6. Thus, hybrimYcin Bl is 2-hydroxyneomYcin C (Fig. 12) . These techniques have combined to establish hybrimycins Al and A2 as 2-hydroxyneomYcins B and C and hybrimYcins Bl and B2 as 2-epihydroxyneomYcins B and C. Additional confirmation of the structural assignments derives from hydrolysis of hybrimYcins Al and A2 to hybrimYcin A3, a neamine analog and similar hydrolytic results with hybrimycins Bl and B2 to give hybrimYCin B3. The structure assigned to 6-deoxyneomYcin (Fig. 12) by Gero, et !!· (19), was based on hydrolytic experiments, which gave 6-deoxyneamine (which in turn gave 2,6-dideoxystreptamine) and methyl neobiosaminides B and C.
2,5-0ideoxystreptamine cannot, of course, give a neomycin analog, since it lacks the requisite 5-hydroxyl group for attachment to ribose. Thus, the mutasynthetic antibiotic produced is an analog of neamine instead, i·~·· 5-deoxyneamine. The latter compound has recently been prepared synthetically by Suami, et al. (24), and it is of some interest to compare the two routes, as shown in Fig. 17 . The synthetic route starts with neamine (thus, ultimately, with neomYcin) and gives 5-deoxyneamine in 9% yield after 9 steps (24). The mutasynthetic route starts with 1,4-cyclohexadiene and requires 5 steps to produce 2,5-dideoxystreptamine in 24% yield (25), which is then converted mutasynthetically in one step to 5-deoxyneamine. The mutasynthetic procedure is clearly simpler, though the overall yield depends on the percentage incorporation of 2,5-dideoxystreptamine into 5-deoxyneamine. In addition to the work described above with StreptoffiYces fradiae, mutasynthetfc studies have also been carried out with a number of other microorganisms which produce aminocyclitol antibiotics. ParomomJcin (Fig. 1 ) is produced as a minor component of crude neomycin; thus, it is not surprising that Streptomyces rimosus forma paromomycinus, which produces paromomycin, can be induced to mutate to a non-producing strain which cannot form deoxystreptamine. The mutant strain of ~-rimosus has thus far only been shown to ac.cept two mutasynthons: streptamine, which produces the mutasynthetic antibiotics hybrimYcins Cl and C2 (14) , and 2,6-dideoxystreptamine, which produces 6-deoxyparamomycins I and II (19). Structures of these antibiotics (Fig. 18) Since ribostamYcin is actually apart of neomJCin ( Fig. 1) , one might ~ priori expect the mutasynthetic technique tobe successful with StreptomYces ribosidificus, which produces ribostamJCin. This has been confirmed by Kojima and Satoh in the Meiji Seika laboratories (26). The deoxystreptamine-lacking mutant of ~-ribosidificus was similar to those described above in its acceptance of deoxystreptamine-related mutasynthons (Fig. 19 ) but was unusual in that it accepted neamine as well as deoxystreptamine, and gave a mutasynthetic antibiotic (3',4'-dideoxyribostamycin) from 3' ,4'-dideoxyneamine (26). This argues that the biosynthesis of ribostamycin proceeds from deoxystreptamine to neamine to ribostamYcin, which probably has significance for the biosynthesis of neomJcin as well. The structures of the mutasynthetic ribostamycin analogs were established by mass spectrometric comparison to that of ribostamJcin. The mutasynthetic route to 3' ,4'-dideoxyribostamycin (which starts with neamine) (27) can be compared to the purely synthetic route, which starts with ribostamYcin ( Fig. 20) {28) .
A D-mutant has also been reported recently from Bacillus circulans, which normally produces butirosin, a ribostamycin derivative (29). Unlike the ~-ribosidificus mutant, it did not form the parent antibiotic (butirosin) in the presence of neamine (or of ribostamYcin, or of the 1-N-k-{y-amino-a-hydroxybutyryl) derivatives of deoxystreptamine or neamine (Fig. 21) .
The o-mutant of B. circulans has been employed to prepare 2-hydroxybutirosin from streptamine and 5-deoxybutirosamine from 2,5-dideoxystreptamine. The structures of the mutasynthetic antibiotics were assigned by hydrolysis to subunits and by mass spectra of the antibiotics' N-acetyl 0-methyl derivatives, which are of lower molecular weight than the 0-trimsyl analogs.
We shall now shift from the 4,5-to the 4,6-disubstituted deoxystreptamine antibiotics (Fig. 2) . Mutants of ~-kana ceticus which cannot synthesize deoxystreptamine have been obtained both in our laboratory 14 and those of Meiji Seika (Kojima and Satoh) (26). Pseudodisaccharides such as neamine, kanosaminyl-deoxystreptamine, or 6-amino-6-deoxyglucosyl-deoxystreptamine are not incorporated. Similar results with regard to potential mutasynthon specificity were obtained by both groups. 2-Epistreptamine was incorporated in both laboratories and N-methyldeoxystreptamine by Kojima and Satoh. Structures of the two mutasynthetic antibiotics from 2-epistreptamine and 1-N-methyldeoxystreptamine ( Fig. 22) were, surprisingly, not the simple analogs resulting from one-toone replacement of deoxystreptamine by the mutasynthon. In addition, the 6-aminoglucose moiety of kanamycin was replaced in both mutasynthetic antibiotics by glucose itself. The ~-kanamyceticus mutant example provides an important caveat for mutasynthetic antibiotic research--that the structures of the antibiotics cannot be assumed but must be proved. Gentamiein is produeed by speeies of the Mieromonospora rather than the Streptogenus. Nevertheless, the biosynthesis of deoxystreptamine ean be presumed to be the same for both genera and the mutasynthetie approaeh eould be antieipated tobe sueeessful. This has been shown to be the ease by Testa, et. !!·• who prepared a mutant of ~· inyo~ ensis whieh eould not form deoxystreptamine (31). This organism normally produees sisomYein, an unsaturated analog of gentamiein Cla, and the o-mutant was able to eonvert the mutasynthons streptamine, 2-epistreptamine, and 2,5-dideoxystreptamine to mutasynthetie antibioties (Fig. 23) , ealled mutamieins. More mutamieins were formed than expeeted and, although the struetures of some of the mutasynthetie antibioties formed were those expeeted, involving simple replaeement of deoxystreptamine by the mutasynthon, the struetures of others involved more extensive ehanges. A 6'-hydroxyl replaces the 6'-amino group of kanamYcin A (Fig. 2) . As noted at the beginning of this discussion of mutasynthetic antibiotics, there are a number of aminocyclitol antibiotics which contain aminocyclitols other than deoxystreptamine.
The most important of these are the Streptomycins, but before turning to mutasynthesis of antibiotics related to streptomycin, we must first discuss the biosynthesis of streptomYcin itself, since it differs somewhat from 1 that of neomYcin and has been even more extensively studied (33,34}. Investigations with 4c-and 13c-labeled glucoses have shown that glucose provides all the carbon atoms of Streptomycin except the N-methyl carbon of N-methyl-hglucosamine (which is derived from methionine} and the guanido carbons of streptidine (which are derived by transfer from arginine}. For the most part the glucose skeleton is incorporated unrearranged ( streptose. Our own attention was primarily directed toward the streptidine ring, and 13c NMR spectroscopy was able to show that C-6 of glucose becomes c-y 3 of streptidine, as well as C-6" of N-methyl-.!:_-glucosamine and C-5' of streptose (35) . The C NMR spectrum of unlabeled ~treptomycin, shown in Fig. 25 , together with the spectrum of Streptomycin labeled by ~-[6-1 C]glucose, was assigned by consideration of the model compounds streptidine, methyl dihydrostreptobiosaminide, N-methyl-1-glucosamine, dibenzyl a-h-dihydrostreptoside (Fig. 26) and dihydrostreptomycin, and the variations in the 13c NMR spectrum of dihydrostreptomycin engendered by changes in pH (Fig. 27) The differences between the biosyntheses of deoxystreptamine and streptidine are shown first by the difference in labeling of the aminocyclitol by C-l of glucose, which labels C-l of deoxystreptamine but C-5 of streptidine, and by C-6 of glucose, which labels C-2 of deoxystreptamine but C-6 of streptidine. Moreover, ~-inositol is not incorporated into deoxystreptamine (12) but is incorporated well into streptidine (33) . Finally, while deoxystreptamine is incorporated well into neomycin, streptamine has been reported not to be incorporated specifically into Streptomycin (37) . All of these considerations are well accounted for by the biosynthetic scheme proposed for streptidine by Walker ( Fig. 28) (38) .
With the differences between the biosyntheses of streptidine and deoxystreptamine in mind, it is clear why streptamine should not be incorporated into Streptomycin: it never appears on the biosynthetic pathway of Fig. 28 . On the other hand, streptidine itself does appear on the pathway, at least as its 6-phosphate, which is hydrolyzed in a perhaps reversible reaction. Curiously, no one appears to have tried to incorporate labeled streptidine into streptomycin, though streptamine was shown early to label all three C6 subunits of Streptomycin (37). Shier early made brief attempts to obtain a mutant of i· gY'iseus lacking the ability to form streptidine(an s-mutant) but was unsuccessful (39). More recently, (36) .
The location of the urethan group of bluensomYcin (Fig. 3) can be assigned from the changes in chemical shift of the streptidine carbons (36) . Nagaoka and Demain have been successful in obtaining such an s-mutant and have also been successful in employing the mutasynthetic approach by adding the mutasynthon 2-deoxystreptidine to a growing cult.ure of the mutant to produce an antibiotic different from Streptomycin ( Fig. 29) (40) . Thus far, the mutasynthetic antibiotic bas not been isolated or characterized, so it is unclear whether it represents a simple replacement of streptidine by deoxystreptidine or a more extensively modified antibiotic. The final example of mutasynthesis involves Streptomocces spectabilis, which produces the aminocyclitol antib,iotic spectinomycin (as well as the unrelated ansamycin antibiotic streptovaricin, but that is a separate subject). As noted above, spectinomycin (Fig. 3) contains the aminocyclitol actinamine (N,N'-dimethyl-2-epistreptamine) and actinamine's biosynthesis might resemble that of deoxystreptamine or that of streptidine. The biosynthesis of spectinomycin has been investigated by our own group (41) and those of Mitscher and Martin (42) and by Slechta and Coats (43) and, in fact, there are elements of both the deoxystreptamine and the streptidine patterns involved in actinamine biosynthesis.
The labeling pattern from ~- [6-13c] glucose resembles that of streptidine rather than that of deoxystreptamine (Fi~. 30) (41) . The l3c NMR spectra of unlabeled spectinomycin and of the antibiotic from the [6-13c] glucose feeding are shown in Fig. 31 . Carbon atoms were assigned by comparison with actinamine and by shifts of carbons with varying pH. ~-Inositol is incorporated into actinamine·, as it is into streptidine (42). On the other hand, 2-epistreptamine (didemethylactinamine) is also incorporated into actinamine (43), whereas streptamine is not incorporated into streptidine. A mutant of ~· spectabilis which cannot synthesize actinamine (an A-mutant) was employed in the last experiment and in separate experiments tritium-labeled actinamine, 2-epistreptamine + [methyl-14c]methionine and Nmethyl-2-epistreptamine all gave labeled spectinomycin, identified by spots which were both radioactive and antibacterial (Fig. 32) .
The same A-mutant was also used in mut~synthetic experiments employing streptamine in the presence of [methyl-14c]methionine or [ H]N,N'-dimethylstreptamine, which both gave radioactive spots near those for spectinomycin. However, there was no antibacterial activity associated with the material from these experiments (Fig. 33) . The mutasynthetic product was not isolated, but its most likely structure is 2-epispectinomYcin. However, it would have to be biologically inactive, a rather surprising result. 2-EpispectinomYcin has recently been synthesized (44) by chemical modification of spectinomycin (Fig. 34 ) and the compound is indeed devoid of antibacterial activity (Figs. 31 ,32 ). While this does not prove the structure of the mutasynthetic product from the i· spectabilis mutant, it lends credibility to a likely 2-epispectinomYcin structure. Since the usual rapid assay for incorporation of a mutasynthon has been a test for antimicrobial activity, Fig. 34 . Conversion of spectinomYcin to bioinactive 2-epispectinomycin (44).
we have long recognized the possibility of incorporation to give a bioinactive product. However, the recently demonstrated inactivity of 2-epispectinomycin lends additional impetus to a reinvestigation (using radioactive mutasynthons) of many of the aminocyclitols which did not give new antibiotics.
We have now described all of the mutasynthetic aminocyclitol antibiotics thus far reported and can summarize them in Table 1 . Four steps in a mutasynthesis study were listed earlier--1) preparation and 2) incorporation of the mutasynthons, and 3) isolation and characterization and 4) evaluation of the mutasynthetic antibiotics. The last step has not been discussed until now, but it represents, in a sense, the "bottoin line" of a mutasynthetic investigation. In ordertobe developed the new antibiotics must have advantages overthose previously available. Very little definitive information has thus far appeared, perhaps because yields of the mutasynthetic antibiotics are usually not very high and evaluation of any new drug is time-consuming. The most abundant information is that available for the hybrimycins (see below) but the fragmentary information on others is summarized in Table 2 .
The hybrimycins have been compared with several other aminocyclitol antibiotics for their activity against twelve microorganisms (46). The order of bioactivity observed was gentamiein > hybrimycin A > neomycin ~ kanamycin B > hybrimycin B > ribostamycin. A similar order was observed against Mycobacterium tuberculosis. In a more extensive comparison against 56 microorganisms hybrimycin Al and neomycin were of similar activity; again, hybrimycin B was less active. The mode of action of the hybrimycins is the same as that of their parent antibiotics, the neomycins, which cause misreading of the ribosemal codon (47).
Since the antibacterial activities of the hybrimycins are at best about as high as those of the corresponding neomycins their principal clinical interest would appear to lie in their potentiality for reduced toxicity. Results along these lines have only very recently become available and they are quite encouraging. The acute toxicities (intravenous and subcutaneous) of both hybrimycins A and B are somewhat less than those of neomycin. More importantly, the nephrotoxicity and hepatotoxicity of hybrimycin A are much lower (ca. one-half) than those of neomycin and hybrimycin B (46).
Though these initial biological evaluations are less than spectacular, the future of the mutasynthetic approach appears quite promising. Presumably some day a superior mutasynthetic antibiotic will be prepared. Moreover, the technique can be employed for other purposes--the study of structure-activity relationships, the investigation of enzyme '',. \ specificity, the preparation of specifically labeled antibiotics, etc. Although the aminocyclitol antibiotics lend themselves especially well to mutasynthesis, any antibiotic with a discreet, preferably unusual, subunit which is incorporated directly into the antibiotic is a candidate for the mutasynthetic technique, as has been demonstrated recently by the mutasynthesis of analogs of novabioein {48,49).
In Notes added in P.roof: Very recent stuäies with a deoxystreptamine-lacking mutant of Micromonosaora ur urea have demonstrated that streptamine and 2,5-dideoxystreptamine are incorporate by t 1s mutant into 2-hydroxygentamicins and 5-deoxygentamicins, respectively, and that addition of 2,4,6/3,5-pentahydroxycyclohexanone (~-inosose, scyll)-inosose) gives 2-hydroxygentamicins while 2~4/3A5-tetrahydroxycyclohexanone (a deoxyinosose gives the gentamieins complex itsel f. o0-5~
RE FE RENCES

